{"nctId":"NCT00424463","briefTitle":"Expanded Controlled Study of Safety and Efficacy of MCI-186 in Patients With Amyotrophic Lateral Sclerosis (ALS)","startDateStruct":{"date":"2007-01"},"conditions":["Amyotrophic Lateral Sclerosis (ALS)"],"count":181,"armGroups":[{"label":"1","type":"EXPERIMENTAL","interventionNames":["Drug: MCI-186"]},{"label":"2","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo of MCI-186"]}],"interventions":[{"name":"MCI-186","otherNames":["Edaravone","Radicut"]},{"name":"Placebo of MCI-186","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Patients who ware completed drug administration without discontinuation in the preceding confirmatory study NCT00330681.\n\nExclusion Criteria:\n\n* Patients with such complications as Parkinson's disease, schizophrenia, dementia, renal failure, or other severe complication, and patients who have the anamnesis of hypersensitivity to edaravone.\n* Patients whose creatinine clearance is 50mL/min or less at the time of completion of drug administration in the study NCT00330681.\n* Pregnant, lactating, and probably pregnant patients, and patients who want to become pregnant, and patients who can not agree to contraception.\n* Patients who are participating in other clinical trials except the study NCT00330681.\n* In addition to the above exclusion criteria, patients judged to be inadequate to participate in this study by their physician.","healthyVolunteers":false,"sex":"ALL","minimumAge":"20 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":false},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline in Revised ALS Functional Rating Scale (ALSFRS-R) Score in Full Analysis Set (FAS) Population at 24 Weeks","description":"0=worst; 48=best To investigate the sustainability of effects of edaravone, the analysis focusing on the comparison between the placebo and edaravone groups of patients who had received 6 cycles of edaravone treatment, i.e., the comparison of data from Cycles 7 to 12 between the edaravone-edaravone group and the edaravone-placebo group, was performed.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-5.5","spread":"4.6"},{"groupId":"OG001","value":"-4.2","spread":"4"},{"groupId":"OG002","value":"-5.4","spread":"4.5"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Death or a Specified State of Disease Progression","description":"Any of \"death, disability of independent ambulation, loss of upper arm function, tracheotomy, use of respirator, and use of tube feeding\" was defined as an event.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"1","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"8","spread":null},{"groupId":"OG001","value":"11","spread":null},{"groupId":"OG002","value":"20","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"5","spread":null},{"groupId":"OG002","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1","spread":null},{"groupId":"OG001","value":"1","spread":null},{"groupId":"OG002","value":"8","spread":null}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in % Forced Vital Capacity (%FVC) in Full Analysis Set (FAS) Population at 24 Weeks","description":"To investigate the sustainability of effects of edaravone, the analysis focusing on the comparison between the placebo and edaravone groups of patients who had received 6 cycles of edaravone treatment, i.e., the comparison of data from Cycles 7 to 12 between the edaravone-edaravone group and the edaravone-placebo group, was performed.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-10.6","spread":"13.16"},{"groupId":"OG001","value":"-12.91","spread":"14.97"},{"groupId":"OG002","value":"-10.54","spread":"13.21"}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Events","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"97.8","spread":null},{"groupId":"OG001","value":"91.7","spread":null},{"groupId":"OG002","value":"92","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Adverse Drug Reactions","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.4","spread":null},{"groupId":"OG001","value":"10.4","spread":null},{"groupId":"OG002","value":"10.2","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Laboratory Tests for Which the Incidence of Abnormal Changes Was 5% or Higher in Either Group","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"11.1","spread":null},{"groupId":"OG001","value":"4.2","spread":null},{"groupId":"OG002","value":"10.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"6.3","spread":null},{"groupId":"OG002","value":"4.5","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"6.3","spread":null},{"groupId":"OG002","value":"3.4","spread":null}]}]}]},{"type":"SECONDARY","title":"Percentage of Participants With Abnormal Changes in Sensory Examinations","description":null,"paramType":"NUMBER","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"2.1","spread":null},{"groupId":"OG002","value":"2.3","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0","spread":null},{"groupId":"OG001","value":"0","spread":null},{"groupId":"OG002","value":"0","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":13,"n":45},"commonTop":["Nasopharyngitis","Gait disturbance","Constipation","Contusion","Insomnia"]}}}